



EDITED BY
IQBAL RAMZAN

BIOLOGICS, BIOSIMILARS, AND BIOBETTERS


AN INTRODUCTION FOR PHARMACISTS,
PHYSICIANS, AND OTHER HEALTH PRACTITIONERS



Innovator Biologic



Biosimilar



Biobetter

WILEY

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Foreword](#)

[Preface](#)

[1 Innovator Biologics, Biosimilars, and Biobetters:
Terminology, Nomenclature, and Definitions](#)

[Abbreviations](#)

[1.1 Place of Biologics in Modern Therapeutics](#)

[1.2 Background to Terminology, Nomenclature, and
Definitions](#)

[1.3 Innovator Biologics, Biosimilars, and Biobetters](#)

[1.4 Differences Between Biosimilars and Generic
Medicines](#)

[1.5 Interchangeability, Switchability, and
Substitution](#)

[1.6 Other Clinical Considerations with Biosimilars](#)

[1.7 Manufacture, Delivery, and Naming
Considerations](#)

[1.8 Listing of Approved Biologics](#)

[1.9 Biosimilar Initiatives and Organizations](#)

[1.10 Common Terms Used in the Biologics
Literature](#)

[1.11 Abbreviations Associated with Biologic
Medicines](#)

[1.12 Concluding Remarks](#)

[Acknowledgement](#)

[References](#)

[2 Approved Biologic Medicines and Biosimilars in Major Regulatory Jurisdictions](#)

[Abbreviations](#)

[2.1 Regulatory Frameworks](#)

[2.2 Major Regulatory Jurisdictions](#)

[2.3 Maturation of the Biologic Market](#)

[2.4 Player Archetypes in a Maturing Market](#)

[2.5 Outlook: Landscape of the Biologic Market](#)

[2.6 Technology and Science Innovation in the Long Term?](#)

[2.7 The Arrival of Major Biosimilars](#)

[2.8 Biosimilars in Emerging Markets](#)

[2.9 Top 10 Biologic Drugs in the United States](#)

[2.10 Top 10 Biologic Drugs in the EU](#)

[2.11 Conclusions](#)

[References](#)

[3 Status of Biologic Drugs in Modern Therapeutics-Targeted Therapies vs. Small Molecule Drugs](#)

[Abbreviations](#)

[3.1 Biologics in Contemporary Medicine](#)

[3.2 Clinical Characteristics of Biologic Drugs](#)

[3.3 rDNA and Biologic Drug Manufacturing](#)

[3.4 What Does the Future Hold?](#)

[3.5 Global Biologics Market](#)

[3.6 Summary](#)

[References](#)

[4 Major Classes of Biotherapeutics](#)

Abbreviations

4.1 Major Classes of Biotherapeutics

4.2 Antibodies and Antibody-Based Therapeutics

4.3 Alternative mAb-Based Therapeutics

4.4 Therapeutic Signaling Molecules

4.5 Blood-Related Products

4.6 Biosimilars

References

5 Drug Targets for Biologics

Abbreviations

5.1 Introduction

5.2 Immune Checkpoints

5.3 Human Epidermal Growth Factor Family

5.4 Vascular Endothelial Growth Factor

5.5 Interleukins

5.6 Tumor Necrosis Factor

5.7 Receptor Activator of Nuclear Factor- κ B Ligand (RANKL)

5.8 Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

5.9 Concluding Remarks

References

6 Pivotal Biology, Chemistry, Biochemistry, and Biophysical Concepts of Biologics and Biosimilars

Abbreviations

6.1 Definitions: Biologics vs. Small Molecule Drugs

6.2 Biochemical and Biophysical Properties

6.3 Chemical and Physical Stability

6.4 Formulation Considerations and Devices

[6.5 Analytical Methods/Tools](#)

[6.6 Influenza Vaccines](#)

[References](#)

[7 Biosimilarity and Interchangeability of Biologic Drugs- General Principles, Biophysical Tests, and Clinical Requirements to Demonstrate Biosimilarity](#)

[Abbreviations](#)

[7.1 Introduction](#)

[7.2 Interchangeability](#)

[7.3 Conclusions](#)

[References](#)

[8 Pharmacokinetics of Biologics](#)

[Abbreviations](#)

[8.1 Introduction](#)

[8.2 Pharmacokinetics and Pharmacodynamics of Biological Medicines](#)

[8.3 Understanding Pharmacokinetic Variability for Monoclonal Antibodies](#)

[8.4 Pharmacokinetics of Biosimilar and Biobetter Biologics](#)

[8.5 Modeling and Simulation of Monoclonal Antibody Pharmacokinetics and Pharmacodynamics](#)

[8.6 Individualizing Therapy and the Role of TDM](#)

[8.7 Conclusions](#)

[Acknowledgements](#)

[References](#)

[9 Pharmacogenomics of Biologics](#)

[Abbreviations](#)

[9.1 Introduction](#)

[9.2 Approaches to the Identification of Genetic Variants Influencing Response to Biologic Medicines](#)

[9.3 Pharmacogenomics of Biologics in Rheumatoid Arthritis](#)

[9.4 Pharmacogenomics of Biologics in Inflammatory Bowel Disease \(IBD\)](#)

[9.5 Pharmacogenomics of Biologics in Psoriasis](#)

[9.6 Pharmacogenomics of Biologics in Age-Related Macular Degeneration \(AMD\)](#)

[9.7 Pharmacogenomics of Biologics in Asthma and Chronic Obstructive Pulmonary Disease](#)

[9.8 Conclusions](#)

[References](#)

[10 International Regulatory Processes and Policies for Innovator Biologics, Biosimilars, and Biobetters](#)

[Abbreviations](#)

[10.1 Introduction](#)

[10.2 Major International Regulatory Agencies](#)

[10.3 General Requirements for Biologics Approval](#)

[10.4 Specific Requirements for Innovator/Reference Biologics and Biosimilars](#)

[10.5 Approval of Biobetters](#)

[10.6 Conclusions](#)

[References](#)

[11 Pharmacovigilance of Innovator Biologics and Biosimilars](#)

[Abbreviations](#)

[11.1 Introduction](#)

[11.2 Premarketing Period](#)

[11.3 Post-marketing Period](#)

[11.4 New Directions](#)

[11.5 Conclusions](#)

[References](#)

[12 Pharmacoeconomics of Biologic Medicines and Biosimilars](#)

[Abbreviations](#)

[12.1 Pharmacoeconomics of Innovator Biologics](#)

[12.2 Variation in Usage of Innovator Biologics](#)

[12.3 Payer Management of Innovator Biologic Costs](#)

[12.4 Value of Innovator Biologics](#)

[12.5 Innovator Biologic Development Costs](#)

[12.6 Coverage of Rare Disease Drugs](#)

[12.7 Pharmacoeconomics of Biosimilars](#)

[12.8 Conclusions](#)

[References](#)

[13 New Emerging Biotherapies: Cutting-Edge Research to Experimental Therapies](#)

[Abbreviations](#)

[13.1 Introduction](#)

[13.2 Methods to Enhance Stability of Biologics](#)

[13.3 Bispecific Antibodies \(bsAbs\)](#)

[13.4 Antibody-Drug Conjugates](#)

[13.5 CAR T-cell Therapy](#)

[13.6 Immune Checkpoint Antagonism](#)

[13.7 Conclusions and Future Outlook](#)

[References](#)

[14 Optimizing Use of Biologic Medicines Using a Quality Use of Medicines Approach](#)

Abbreviations

14.1 Introduction

14.2 Quality Use of Medicines Approach

14.3 Influences on Prescribing and Use of Biologic Medicines

14.4 Policy to Support Appropriate Uptake of Biologic Medicines

14.5 Formulary Management

14.6 Sources of Information and Education

14.7 Adherence and Persistence

14.8 Cost-effectiveness Considerations

14.9 Monitoring and Real-World Experience

14.10 Conclusions

References

15 Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students

Abbreviations

15.1 Chapter Background

15.2 Current Knowledge of Pharmacists and Pharmacy Students About Biologics

15.3 Prescriber Knowledge of Biologic Medicines

15.4 Pharmacist's Role in Biologic Medicine Education

15.5 General Background on Biologic Medicines

15.6 History of Pharmacy Education

15.7 Accreditation of Pharmacy Degrees

15.8 Content of Pharmacy Degree Curricula

15.9 Recommended Knowledge Areas on Biologics in the Published Literature

[15.10 Modes of Learning and Teaching Delivery and Assessments](#)

[15.11 Urgent Need for Curriculum Reform](#)

[15.12 Concluding Remarks](#)

[References](#)

[16 A Checklist for Pharmacists on Biologics and Biosimilars: Tips to Enhance Patient-Centered Discussions](#)

[Abbreviations](#)

[16.1 Context of This Checklist for Pharmacists and Health Professionals](#)

[16.2 Summary of Biologics, Biosimilars, and Biobetters](#)

[16.3 Storage and Handling of Biologics](#)

[16.4 Regulatory Requirements](#)

[16.5 Naming and Labeling of Biologic Therapies](#)

[16.6 Funding of Biosimilars: Australian Approach](#)

[16.7 Pharmacovigilance](#)

[16.8 Medicines Use Evaluation](#)

[16.9 Reducing Clinical Risks from Innovator Biologics, Biosimilars, and Biobetters](#)

[16.10 Checklist on Biologics](#)

[16.11 Practice Points: Anticipated Questions from Health Professionals](#)

[16.12 Practice Points: Anticipated Questions from Patients](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 1

[Table 1.1 Broad categories of biologic medicines.](#)

[Table 1.2 Definitions of biosimilars by major regulatory agencies.](#)

[Table 1.3 Pivotal differences between biologics and small molecule drugs.](#)

[Table 1.4 Abbreviations used in biologic medicine literature.](#)

Chapter 3

[Table 3.1 Best-selling drugs ranked by sales volume.](#)

[Table 3.2 Characteristics of small molecule pharmaceuticals vs. biologics.](#)

[Table 3.3 Preclinical and clinical trial data exclusivity by nation.](#)

[Table 3.4 A history of vaccine development and regulation in the United State...](#)

[Table 3.5 Examples of cytokine drugs and diseases treated.](#)

[Table 3.6 Insulin: timeline of discovery and manufacture.](#)

Chapter 4

[Table 4.1 Major classes of biotherapeutics.](#)

Chapter 6

[Table 6.1 Comparison of common characteristics of biologics and small molecul...](#)

[Table 6.2 Nomenclature/naming of therapeutic monoclonal antibodies.](#)

[Table 6.3 Summary of commonly used biophysical methods used in biologics rese...](#)

Chapter 7

[Table 7.1 Representative example of quality attributes for a monoclonal antib...](#)

Chapter 8

[Table 8.1 Monoclonal antibody nomenclature, humanized component, and examples...](#)

[Table 8.2 Pharmaceutical, pharmacokinetic, and pharmacodynamic differences be...](#)

[Table 8.3 Pharmacokinetic parameters for selected therapeutic proteins includ...](#)

[Table 8.4 Examples of monoclonal antibodies with membrane-bound and shed targ...](#)

[Table 8.5 Drug interactions involving monoclonal antibodies.](#)^{2,49}

Chapter 10

[Table 10.1 Comparison of biosimilar regulations and guidelines internationall...](#)

Chapter 11

[Table 11.1 Pharmacovigilance signal refinement.](#)⁴¹

[Table 11.2 Advantages and limitations of spontaneous reporting systems.](#)⁵⁴

Chapter 12

[Table 12.1 Examples of incentives and disincentives for biosimilar adoption.](#)

Chapter 13

[Table 13.1 Some critical properties of approved antibody-drug conjugates \(ADC...](#)

[Table 13.2 Current immune checkpoint inhibitors in clinical use.](#)

Chapter 14

[Table 14.1 Considerations for PTC members evaluating biosimilars for formular...](#)

[Table 14.2 Steps for implementation of an interchangeability program for bios...](#)

Chapter 15

[Table 15.1 Core knowledge areas for pharmacists and pharmacy students.](#)

Chapter 16

[Table 16.1 Summary information on selected biologic therapies.^{1, 2, 5, 7, 20-...}](#)

[Table 16.2 Regulatory differences - comparison of biosimilars and generics of...](#)

[Table 16.3 The principles of naming monoclonal antibodies.³⁵](#)

[Table 16.4 An example of infliximab listing on the Pharmaceutical Benefits Sc...](#)

[Table 16.5 Checklist for pharmacists for safe and effective use of biologic t...](#)

List of Illustrations

Chapter 3

[Figure 3.1 Relative molecular mass of small molecule and biologic drugs.](#)

Chapter 4

[Figure 4.1 Structure of IgG1. \(a\) Schematic representation of an IgG1 displa...](#)

[Figure 4.2 Structural features of various classes of therapeutic proteins.](#)

Chapter 5

[Figure 5.1 CTLA-4 and PD-1/PD-L1 blockade using immune checkpoint inhibitors...](#)

[Figure 5.2 Extracellular domain structures of EGFR bound to EGF \(PDB ID: 3NJ...](#)

[Figure 5.3 Mechanism of action of TNF- \$\alpha\$ biologics; infliximab is shown bindi...](#)

Chapter 6

[Figure 6.1 \(a\) Primary, secondary, tertiary, and quaternary protein structur...](#)

[Figure 6.2 Types of N-glycans observed in therapeutic proteins. All N-glycan...](#)

[Figure 6.3 Post-translational \$\gamma\$ -carboxylation of glutamate residues in prote...](#)

[Figure 6.4 An IgG1 antibody with 4 interchain \(green\) and 12 intra-chain dis...](#)

[Figure 6.5 Native and non-native protein aggregation.](#)

[Figure 6.6 Different size particles present in an influenza vaccine sample a...](#)

Chapter 7

[Figure 7.1 Development paradigm of biosimilars versus innovators.](#)

[Figure 7.2 Quality attribute ranges of a biosimilar candidate and its refere...](#)

[Figure 7.3 Time line of EMA and FDA biosimilar approvals.](#)

[Figure 7.4 Elements of the optimal switching study and study designs employ...](#)

Chapter 8

[Figure 8.1 Graph summarizing the pharmacokinetic features of therapeutic pro...](#)

[Figure 8.2 Schematic summarizing the many unique factors that influence the ...](#)

[Figure 8.3 The process of receptor-mediated endocytosis and FcRn recycling o...](#)

[Figure 8.4 The impact of antidrug antibodies on the pharmacokinetics and pha...](#)

Chapter 13

[Figure 13.1 CAR T-cell therapy treatment.](#)

[Figure 13.2 Cartoon illustration of the evolution of CAR-T therapies.](#)

[Figure 13.3 Comparison of MultiTAA and CAR T-cell therapy.](#)

[Figure 13.4 Antagonism of immune checkpoint receptors.](#)

Chapter 15

[Figure 15.1 Pharmacy curriculum reform framework on biologics.](#)

Biologics, Biosimilars, and Biobetters

**An Introduction for Pharmacists,
Physicians, and Other Health
Practitioners**

Edited by

Iqbal Ramzan

*Sydney Pharmacy School, Faculty of Medicine and Health
The University of Sydney
Sydney, New South Wales, Australia*

WILEY

This edition first published 2021
© 2021 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Iqbal Ramzan to be identified as the author of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data Applied for:

ISBN: 9781119564652

Cover Design: Wiley

Cover Image: Courtesy of David Hibbs. Image based on Protein Database ID (PDBID): 1IGY - Structure of Immunoglobulin, organism *Mus musculus* (Harris, *et al.* (1998); Crystallographic structure of an intact IgG1 monoclonal antibody at *J. Mol. Biol.* 275: 861-872), created with the Maestro program (Schrödinger LLC). Natural outdoors bokeh background in green and blue tones with sun rays © guvendemir/Getty Images

List of Contributors

Jeffry Adiwidjaja

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Esteban Cruz

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Hans C. Ebbers

Scientific Affairs Biosimilars
Biogen International GmbH
Baar
Switzerland

Paul W. Groundwater

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Jane R. Hanrahan

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney

Sydney
New South Wales
Australia

Bryson A. Hawkins

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

David E. Hibbs

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Kevin Huang

Department of Medicine
Harvard Medical School
Boston
MA
USA

Prateek Jain

Independent consultant
Toronto, Canada

Reza Kahlaee

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Veysel Kayser

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Felcia Lai

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Christine Y. Lu

Department of Population Medicine
Harvard Medical School and Harvard
Pilgrim Health Care Institute
Boston
MA
USA

Hemant Malhotra

Department of Medical Oncology
Sri Ram Cancer Center
Mahatma Gandhi Medical College Hospital
Jaipur
India

Andrew J. McLachlan

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Cody Midlam

Willis Towers Watson
Cincinnati OH
USA

Sanja Mirkov

School of Pharmacy
The University of Auckland
Auckland
New Zealand
Ramsay Pharmacy Services
Melbourne
Victoria
Australia

Catherine A. Panozzo

Department of Population Medicine
Harvard Medical School and Harvard Pilgrim Health Care
Institute
Boston MA
USA

Ankur Punia

Department of Medical Oncology
Sri Ram Cancer Center
Mahatma Gandhi Medical College Hospital
Jaipur
India

Iqbal Ramzan

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Gregory Reardon

School of Pharmacy and Health Sciences
Keck Graduate Institute
Claremont CA
USA

Mouhamad Reslan

Sydney Pharmacy School
Faculty of Medicine and Health
The University of Sydney
Sydney
New South Wales
Australia

Johan Rosman

Medical School
Curtin University Perth
Western Australia
Australia

Mehmet Sen

Department of Biology and Biochemistry
University of Houston
Houston TX
USA

Michael Ward

Clinical and Health Sciences
University of South Australia
Adelaide South Australia
Australia

Lynn Weekes

Health Strategy and Sciences
Sydney New South Wales Australia
School of Pharmacy University of Queensland
St. Lucia Queensland
Australia

Foreword

Tracing back through history, one observes that the treatment of human disease, while always multimodal, has been strongly influenced, and even dominated, by select therapeutic strategies for discrete periods of time. Examples include the use of herbs to treat disease in prehistoric times (herbalism), bloodletting and humorism (starting around 500 years before the Christian era), germ theory, and chemotherapy (in the eighteenth and nineteenth centuries). Although the use of chemicals for medicine may be traced back to Paracelsus in the sixteenth century, pharmacotherapy with small molecule drugs (SMDs) did not dominate medicine until the twentieth century. At present, early in the twenty-first century, thousands of SMDs are in use as treatments for virtually all human diseases and conditions, including infectious disease, cardiovascular disease, mental health, pain, diabetes, and cancer.

The use of antibodies to treat disease may be traced to the 1890s, with the application of antisera to treat and prevent toxicity relating to diphtheria. Exogenous insulin was first used to treat diabetes in 1922, and human, recombinant insulin became available for therapeutic use in 1978. Building on these successes, and through advancements in the fields of protein chemistry, immunology, and molecular biology, we may now be entering a new phase where biological drugs, including peptides, proteins (e.g. antibodies), nucleic acid therapeutics (siRNA, antisense oligonucleotides, etc.), and cell therapies (T-cells, viruses, bacteriophages, etc.) emerge as dominant treatments for human disease.

At the time of writing this text in 2020, biologics account for more than 50% of new therapeutic entities under development at many major pharmaceutical companies, and monoclonal antibodies (mAbs) may be considered as the largest drug class (with ~75 mAbs approved for therapeutic use). Five of the current top 10 selling drugs are mAbs, including the top selling drug (adalimumab).

Relative to SMD, biologic drugs are often more selective in their actions, which translates to an improved ratio of beneficial effects relative to unwanted toxicity. However, biologics are much larger, and much more complex, than typical SMDs. An average mAb is associated with a molecular weight of ~150 000 Da, more than 30-times the average molecular weight of SMDs. Additionally, most biological drugs are not chemically synthesized, but are produced by biological systems (e.g. cells grown in bioreactors) that are subject to biological variability. Consequently, biological drugs may be most appropriately considered as complex distributions of molecular entities, rather than as unique chemical compositions. Variability exists within and between preparations of a biologic with regard to post-translational modifications (e.g. the extent and nature of glycosylation and sialylation), chemical modifications (e.g. deamidation and oxidation of labile functional groups), presence of aggregates, and the presence of host cell proteins (i.e. proteins relating to the cells used for production of the biologic). These and other product variables have been associated with significant effects on the pharmacokinetics, pharmacodynamics, and safety of the biologic product. As such, pharmacists, physicians, and other healthcare professionals have been faced with uncertainties regarding the safety and utility of preparations of biologics that are marketed as being “biosimilar” to an innovator biologic, or preparations that

are developed as being superior to an innovator product (i.e. “biobetter”).

This text is extremely timely in that it addresses many fundamental scientific, clinical, and regulatory issues relating to innovator biologics, biosimilars, and biobetters, through a thoughtful and detailed collection of 16 chapters. The text, which has been expertly compiled and edited by Dr. Iqbal Ramzan, provides discussion of the major classes of biological drugs, clear presentation of the terminology and nomenclature of the field, review of approved biosimilar and biobetter drugs, biophysical concepts and key biophysical analytical tests, pharmacokinetics, pharmacogenomics, pharmacovigilance, and pharmacoeconomics. The work provides a practical and clinical perspective to the use of biologics and biobetters, including consideration of controversial topics such as the interchangeability of innovator and biosimilar products. This book will serve as an excellent primer for all pharmacists and clinicians as we move forward into what may become a new era of medicine, an era dominated by the use of biological drugs.

Joseph P. Balthasar
University at Buffalo, Buffalo NY USA

Preface

This is a comprehensive primer, study guide, and primary reference text for pharmacists, doctors, and other health practitioners that presents the relevant science, clinical, policy, and regulatory frameworks for biologic medicines. The contents are pitched at a level that is easily understandable and can be immediately applied in everyday practice.

Innovator biologics, their interchangeable equivalents, biosimilars and their more efficacious, successors, biobetters are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, highly complex in their therapeutic and clinical utility and far more expensive. Pharmacists are the primary healthcare professionals who will be expected to provide advice on these drugs as governments and other third-party payers attempt to contain their costs by introducing interchangeable biologic medicine products.

This book explores the current and emerging scientific and clinical practices. It compares different policy and regulatory approaches across countries. There is a focus on what pharmacists need to discuss with doctors and patients about the regulatory approval principles of biosimilars and evidence for interchangeability. Pharmacists and other clinicians require an understanding of the suite of biophysical tests needed to establish similarity, the likely efficacy, safety, and clinical risk(s) of switching not only from an innovator biologic to a biosimilar or a biobetter but also from any biologic medicine to another. Sound clinical and policy decisions will require health professionals to assimilate new types of information to ensure patients

achieve optimal outcomes. This book will help them navigate this complex territory.

The book also provides recommendations for pharmacy educators and accreditors of pharmacy degree programs on the knowledge areas and competency standards to be met by pharmacy students and pharmacists on the entire burgeoning area of biologic medicines. Pragmatic regulatory approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical data and evidence are also provided. A checklist is provided for pharmacists to facilitate conversations with doctors and patients to ensure quality use of medicine for biologic medicines to deliver patient-centered health outcomes.

Like many current health professionals, I had limited or no exposure to biologic medicines when I trained as a pharmacist. However, while serving as Dean of Pharmacy, at University of Sydney, for over 12 years, I had a bird's-eye view of the profession and of many future directions in healthcare. It was clear that pharmacists would be expected to take on a greater educative role with biologic medicines and I did not necessarily believe that they were sufficiently confident or knew enough about all aspects of biologic medicines. I therefore approached Jonathan Rose at Wiley and put forward a book proposal on biologic medicines. With his support, the proposal was approved after several iterations and I managed to assemble a very talented group of scientists and health professionals who were willing to share this journey with me.

Whether you are a pharmacist, a pharmacy student looking forward to entering professional practice, or a family doctor or specialist prescriber, I hope this book will empower you to understand the complexities of biologic medicines so that you can have an evidence-based and objective conversation with your patients. There is much

hype and many anecdotes, and it is critical to separate these from the facts and data that support use of these important new medicines.

Editing this book (and writing two chapters) has been a very challenging task, probably because I underestimated the enormity of the challenge. The sheer breath of the scientific and clinical literature on biologic medicines is breathtaking. In addition, the literature and the evidence base are evolving so rapidly. If I had correctly gauged how much effort it would have taken me, I probably would not have embarked on this assignment. I am very pleased with the outcome largely due to the very able group of chapter contributors who have worked tirelessly with me to get the book pitched at the right level for pharmacists, doctors, and patients.

I want to thank all the contributing authors for their dedication to this book and to working with me to translate all aspects of the complex science to a level that is easily understood by busy time-poor pharmacists and doctors. My sincere thanks also go to the team at Wiley led by Jonathan Rose who has been very supportive from the beginning and Aruna Pragasam for assisting on the book submission.

I would also like to thank my wife, Dr. Lynn Weekes, who has been tremendously encouraging and supportive through this challenging project even though she herself wrote her own book during much of this time. Kimberlee and Justen, your encouragement to finish the project is also appreciated.

I dedicate this book to my late mum (Amma) who gave me such a strong work ethic and taught me perseverance.

Professor Iqbal Ramzan
Sydney Pharmacy School,
Faculty of Medicine and Health,

The University of Sydney,
Sydney, New South Wales, Australia
26 June 2020